{"ticker": {"uuid": "6618f28c-a65c-402a-bbb7-813aed51d699", "symbol": "CLGN", "name": "Collplant Biotechnologies Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE", "summary": "CollPlant Biotechnologies Ltd. has filed a Form F-3 prospectus to register 31,047,068 ordinary shares for resale by selling shareholders. This registration covers 4,464,707 PIPE Shares and 26,582,361 ordinary shares issuable upon exercise of warrants issued in a private placement", "url": "https://www.stocktitan.net/sec-filings/CLGN/f-3-coll-plant-biotechnologies-ltd-foreign-issuer-shelf-registration-a281b3b9b9e4.html", "source_name": "Stock Titan", "published_at": "2026-07-10T02:10:25", "published_display": "10 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Files Prospectus for Resale of 31 Million Shares", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/collplant-biotechnologies-files-prospectus-resale-212952221.html", "source_name": "MT Newswires", "published_at": "2026-07-09T21:29:52+00:00", "published_display": "09 Jul 2026 21:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Calls July 29 Extraordinary Meeting to Approve Major Share Capital Increase", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxQTm1zQ2N2QkdmbWVCQTBVaDQxWC11M3FKckxLRWhlLXhtSUQ0S21SM2RIRTR4WUxqYk9XZmJhQXhtLUFrX242b1RMNU1aZDlKdUoza3ZFZjd5RUFVY2JpdklGblFwc0ZOSDFaVWdUamdYUWllek9qanBfUzhNaU9nNXFXR2l2VTJraWc4cGlIZTlHTENoY1ltNlVGM19lSnlOMFUtWm05bGEtOEhVLVh4ekZKem5LX2tyZkEybUdRd2ZBblRZWWV4aXdSbDl4N1psQmFRRU5nZzZrcjg3UkoxbEtXemhnaW9UdmQ1RzJzcW9mNTBma1h2TEZGd0FaVjl4cjhlSm01NzVvejZiNlMw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T20:34:00+00:00", "published_display": "08 Jul 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (NASDAQ: CLGN) targets 500M authorized shares in shareholder vote", "summary": "CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is seeking shareholder approval to significantly increase its authorized share capital from 30 million to 500 million Ordinary Shares. This move is intended to provide the company with greater flexibility to fulfill obligations from p", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-344729d5b9a1.html", "source_name": "Stock Titan", "published_at": "2026-07-08T13:10:31", "published_display": "08 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Q4 2025 Earnings: Wider\u2011Than\u2011Expected Loss Highlights Pre\u2011Revenue Challenges - Next Quarter Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPX0hCQ0hPLXJsYldaQl93QnFvWTQ3UmZmZG5TM08yX0ROSW8xTDMyM0xmTkp3aldxaTZ1ZUcwbDZaUWI0c1lvMUhaWklsT1Mzc3YtS0ZCRkRKSl9OOU1IM3RqNTJQV0pHaV9qVW9XS1BtMjFsenVOSXN4VU9aUHRRMHUxM2dGRm8zb1NVZE1fRXQ1bXBIb2Zick1zLUQ2eE95Yk82OTlDbnFDSWdiZ1BJY1ZKWVg3VmhEZHJSMVdKTGIyZDBmNkFQeERpVnRwc01vNW1CeTJSR2ttVUZib1RGYm85UWk5QQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Q4 2025 Earnings: Wider\u2011Than\u2011Expected Loss Highlights Pre\u2011Revenue Challenges", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQcGQzYmc3d18tQjBheS1vZk45dnZxX1BhQXlGYUY0Nlk1VUl2UjZ5bExnU1NMUXlvS0V1TDlBN3FCdGRfek1TZENXYzRSc09yMkUtTXNtWG94blNFM3pCVzEzYzhxd2dnVW9oYUp5VkJBd0dlSTVILVVEOURwRGZpSVpYVm9IcUllem5NN2JzS3lvS3RRZjAzRXJGY3VlZWxja2FVeElwWWc3MzFDcG5CWTNwTE56Y2d0ZTV5b3hkVjdDeW9XY0Q2ckJqQWxLaGVHbXg2MmdiQ1BfaWY3eWdxWjJRS0xQOTBx?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (Nasdaq: CLGN) raises $2.6M in share and warrant private deal", "summary": "CollPlant Biotechnologies has secured $2.6 million through a private placement of ordinary shares and warrants. The funding will be used for general corporate purposes, including working capital, R&D, and evaluating strategic business combinations. H.C. Wainwright & Co. served as", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-1bf3091dbf94.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:40:03", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/collplant-biotechnologies-announces-2-6-120000749.html", "source_name": "PR Newswire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant strikes $2.6M private placement, with warrants attached", "summary": "CollPlant Biotechnologies has announced a definitive agreement for a $2.6 million private placement. The company will issue 7,647,061 ordinary shares (or equivalents) along with Series A and B warrants, priced at $0.34 per share and accompanying warrants. The proceeds are intende", "url": "https://www.stocktitan.net/news/CLGN/collplant-biotechnologies-announces-2-6-million-private-ja22sm9ol512.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:24", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Ltd. announced that it expects to receive $2.6 million in funding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQWkUwckZOa1RjMDRXMEt2NDBnLUNGbWMyUU9nUnZxSmh0Mnl0VEZCLUpWNTlMWFRBVW9EN1A0eVF3ZWJvdzZXSFl3aFhEb3F4MENOd2QwU1h1VXZEQXFTYUpfRXRiNW4wdFNFZHpXTXl4VGFqSG5xa1NCWDlmOER6Zk43NDAtUEhxdFJMZk5QenhVTEFqMzdJeHE0TmU1UUttcE9KT3FfWWVHZFlRZ3lWX2dMNHFBOUdxZHdWOXlnQWtNWEE1cW5uMjN2X3piN3BOQzNVM1VHOGgzVHRqZXVDbg?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T22:00:00+00:00", "published_display": "29 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Ltd Actuals & Estimates (NASDAQ:CLGN)", "summary": "This article provides an overview of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) financial actuals and estimates, including its current stock price, historical performance, market capitalization, and upcoming earnings report. It highlights key financial figures such as recent ea", "url": "https://www.tradingview.com/symbols/NASDAQ-CLGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:42", "published_display": "25 Jun 2026 14:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Faces Pressure Near Key Support - Fair Value Gap", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPQUFzVjdQejN5azV5Wm50aWUwNUFpUWpCZ19xYWk2T01KbHRRZFhUZS04VV9nSkxfZHZXdURmVHZNcDl3YWx0UXZZclRXaW1HNlR1Wk54a2ZDRzBicXo3X25yNXc4Z1JEdjIyWkt4VHN1cVJEVEpWbU9qM19sRko2a3hoT2tDdTdWVE1xbEV1TjVxdkFJVHFtNnRxbFFKRkh3UHliaXRqcTRudzVnb3c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Collplant Biotechnologies Ltd (CLGN), noting that no earnings forecast score is currently available from TradingKey. It highlights an average analyst price target of USD 11.50 for CLGN, with revenue expected to be USD 9.80M for the n", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-21T21:10:17", "published_display": "21 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Institutional Confidence", "summary": "This article analyzes Collplant Biotechnologies Ltd (CLGN)'s institutional confidence score, which is currently 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 27.21% quarter-over-quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clgn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T17:39:23", "published_display": "18 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5WLXdUdVFqbGYwUHplanloWmh4TFY2YUppaElyT01pdGE1b0VSOGdYUF93SHpaSWVJM1FKZllMaFNTUWhBRWZlY1FLNFltMmNDQ09tMjl5b1RMOFFnSk50b2p2RmpZZGU4dVQ2LUoxNENXVl9YSFcw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:53:40+00:00", "published_display": "18 Jun 2026 10:53", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Collplant Biotechnologies Ltd (CLGN) currently holds a financial score of 6.04, placing it 296th out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company recently reported a significant year-over-yea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clgn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:38", "published_display": "18 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CollPlant eyes deals after 50% staff cut and Q1 loss", "summary": "CollPlant Biotechnologies reported a widened GAAP net loss of $3.1 million in Q1 2026, with revenue significantly down to $73,000 from $2.1 million in Q1 2025 due to a non-recurring milestone payment last year. The company reduced its workforce by approximately 50% and initiated ", "url": "https://www.stocktitan.net/news/CLGN/collplant-biotechnologies-reports-2026-first-quarter-financial-q747wn7a7tlf.html", "source_name": "Stock Titan", "published_at": "2026-06-15T15:10:42", "published_display": "15 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents", "summary": "CollPlant (CLGN) is facing a Nasdaq deadline of September 21 to regain compliance with the $1 minimum bid price rule. The company's stock is currently trading under 40 cents, and its Q1 revenue was significantly down due to the absence of a milestone payment received the previous", "url": "https://www.bez-kabli.pl/collplant-heads-toward-nasdaq-deadline-with-stock-at-40-cents/", "source_name": "Bez Kabli", "published_at": "2026-06-04T04:11:01", "published_display": "04 Jun 2026 04:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLGN - CollPlant Biotechnologies Ltd Stock Price and Quote", "summary": "This article provides comprehensive stock information for CollPlant Biotechnologies Ltd (CLGN), including real-time quotes, financial data, company overview, recent news, and analyst ratings. It highlights that the company's last close was at $0.3402, with key financial metrics l", "url": "https://finviz.com/stock?t=CLGN", "source_name": "Finviz", "published_at": "2026-06-03T11:11:50", "published_display": "03 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline", "summary": "CollPlant Biotechnologies reported a wider net loss of $3.1 million in Q1 2026, with revenue dropping significantly to $73,000 from $2.1 million a year prior. The company is actively exploring strategic alternatives, including collaborations for its next-generation dermal fillers", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CLGN-Q/pressreleases/2215852/collplant-biotechnologies-posts-wider-q1-loss-as-it-explores-strategic-alternatives-and-advances-regenerative-aesthetics-pipeline/", "source_name": "The Globe and Mail", "published_at": "2026-05-30T22:09:24", "published_display": "30 May 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Hovers Near Support at $0.38 After Marginal Decline - SuperTrend Flip", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNQlNERTBVTVVBLWtWYUVuWGZ2OUgzMlFZODVvWFRXVVFTdUkwdmplTnE5MVdWaU1scHp0YWFBUWN2VHhCTWhLRVA2TlhFTHdFODRSWGJ1RjVqZk1qb2JwSk94WFpybExTUVNsa1N2LU9GNC1GVGMtZ0JyLWdMemV1Ylh2VnU1azFaMURSZUdSMndwdlZYQ0gwNXpXUFdhRi1qbHQycWVncUNVYW1KaTJGYklpSWgta1lyMzl4U2gxNFBjTmxoYzVUOA?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (NASDAQ: CLGN) Q1 2026 revenue plunges as losses deepen", "summary": "CollPlant (NASDAQ: CLGN) reported a significant decline in Q1 2026 revenue to $73,000 from $2.055 million the previous year, primarily due to the non-recurrence of a $2.0 million milestone payment. The company's GAAP net loss widened to $3.1 million, or $0.23 per share, compared ", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-d216415ba7c4.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:39:39", "published_display": "29 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/collplant-biotechnologies-reports-2026-first-110000012.html", "source_name": "PR Newswire", "published_at": "2026-05-29T11:00:00+00:00", "published_display": "29 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLGN Forecast \u2014 Price Prediction for 2026. Should I Buy CLGN?", "summary": "This article provides a price prediction for Collplant Biotechnologies Ltd (CLGN) stock for 2026 and beyond, based on an advanced algorithm. While short-term predictions show potential volatility and a \"Strong Sell\" recommendation due to negative signals and a falling trend, long", "url": "https://intellectia.ai/stock/CLGN/forecast", "source_name": "Intellectia AI", "published_at": "2026-05-26T02:39:28", "published_display": "26 May 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE", "summary": "CollPlant Biotechnologies has released its second-quarter financial results for 2024, accompanied by a corporate update. This announcement was made via a press release distributed by Quantisnow, a platform providing real-time market data and news to retail investors. The update w", "url": "https://www.quantisnow.com/insight/collplant-biotechnologies-reports-2024-second-quarter-financial-results-and-provides-corporate-update-5665647", "source_name": "Quantisnow", "published_at": "2026-05-23T08:09:27", "published_display": "23 May 2026 08:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CollPlant Biotechnologies (Nasdaq:CLGN) - Stock Analysis", "summary": "This Simply Wall St analysis provides a comprehensive overview of CollPlant Biotechnologies (CLGN), a regenerative and aesthetic medicine company. It highlights a US$6.0m market cap, analyst target price of US$11.56, and significant risks including high share price volatility, de", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clgn/collplant-biotechnologies", "source_name": "Simply Wall Street", "published_at": "2026-05-06T11:09:19", "published_display": "06 May 2026 11:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] CollPlant Biotechnologies Ltd SEC Filing", "summary": "This article reports on an SEC Filing (Form EFFECT) by CollPlant Biotechnologies Ltd (NASDAQ: CLGN). The filing indicates a \"Notice of Effectiveness\" with an effectiveness date of April 21, 2026, at 4:30 P.M. The article details the company's CIK, file number, and provides links ", "url": "https://www.stocktitan.net/sec-filings/CLGN/effect-coll-plant-biotechnologies-ltd-sec-filing-952782470398.html", "source_name": "Stock Titan", "published_at": "2026-04-25T23:39:54", "published_display": "25 Apr 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Half the staff cut as CollPlant resets after AbbVie ends deal", "summary": "CollPlant (CLGN) has announced the termination of its development agreement with AbbVie, leading to a significant company-wide cost-reduction plan that includes a 50% workforce reduction. These measures are expected to extend the company's cash runway into Q4 2026. CollPlant is n", "url": "https://www.stocktitan.net/news/CLGN/coll-plant-issues-letter-to-38jzljmyv08n.html", "source_name": "Stock Titan", "published_at": "2026-04-23T17:10:12", "published_display": "23 Apr 2026 17:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (CLGN) registers 3.296M shares for resale; warrants convertible into shares", "summary": "CollPlant Biotechnologies Ltd. (CLGN) has registered 3.296 million ordinary shares for resale, stemming from the exercise of private placement and placement agent warrants issued in February 2026. The company will not receive proceeds from this resale, but could gain approximatel", "url": "https://www.stocktitan.net/sec-filings/CLGN/424b3-coll-plant-biotechnologies-ltd-prospectus-filed-pursuant-to-rul-3aeca471f162.html", "source_name": "Stock Titan", "published_at": "2026-04-22T05:09:51", "published_display": "22 Apr 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead", "summary": "CollPlant has announced the termination of its development agreement with AbbVie, aiming to seek new strategic partners in the medical aesthetics market for 2026. The company is implementing a cost-reduction plan, including a 50% workforce cut, to extend its cash runway into Q4 2", "url": "https://intellectia.ai/news/stock/collplant-ends-abbvie-partnership-eyes-new-opportunities-ahead", "source_name": "Intellectia AI", "published_at": "2026-04-13T14:09:59", "published_display": "13 Apr 2026 14:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50%", "summary": "CollPlant (NASDAQ: CLGN) announced that AbbVie's Allergan Industrie SAS has terminated their 2021 development agreement for a dermal and soft tissue filler, effective June 8, 2026. In response, CollPlant is implementing a cost-reduction plan, including a 50% workforce cut, to ext", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-a12d95d28f6c.html", "source_name": "Stock Titan", "published_at": "2026-04-13T11:40:15", "published_display": "13 Apr 2026 11:40", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement", "summary": "CollPlant Biotechnologies received a notification from Nasdaq regarding its minimum bid requirement. This alert was sent to Quantisnow Plus members shortly after publication. The company's stock symbol is CLGN and it is categorized under Health Care.", "url": "https://www.quantisnow.com/insight/collplant-biotechnologies-receives-nasdaq-notification-regarding-minimum-bid-requirement-6466833", "source_name": "Quantisnow", "published_at": "2026-04-12T12:39:40", "published_display": "12 Apr 2026 12:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLGN SEC Filings - Collplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms", "summary": "This page on Stock Titan provides comprehensive access to SEC filings for Collplant Biotechnologies Ltd (CLGN), including annual reports (20-F), quarterly reports via 6-K submissions, and documentation of material events. It details the company's regulatory disclosures as a forei", "url": "https://www.stocktitan.net/sec-filings/CLGN/page-4.html", "source_name": "Stock Titan", "published_at": "2026-03-31T20:40:03", "published_display": "31 Mar 2026 20:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (NASDAQ: CLGN) registers 3.296M shares for resale", "summary": "CollPlant Biotechnologies (NASDAQ: CLGN) has registered 3.296 million ordinary shares for resale by existing selling shareholders. These shares are issuable upon the exercise of Private Placement Warrants from a February 2026 financing round. The company will not receive proceeds", "url": "https://www.stocktitan.net/sec-filings/CLGN/f-1-coll-plant-biotechnologies-ltd-foreign-issuer-ipo-registration-7b6caf45d282.html", "source_name": "Stock Titan", "published_at": "2026-03-31T08:40:44", "published_display": "31 Mar 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CollPlant Biotechnologies Launches Redesigned Corporate Website", "summary": "CollPlant Biotechnologies has launched a newly redesigned corporate website. This information was released via Quantisnow, a real-time market data and news platform specializing in aggregating financial information for retail investors. The article briefly mentions recent analyst", "url": "https://www.quantisnow.com/insight/collplant-biotechnologies-launches-redesigned-corporate-website-6455705", "source_name": "Quantisnow", "published_at": "2026-03-29T07:10:13", "published_display": "29 Mar 2026 07:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (Nasdaq: CLGN) 2025 revenue jumps on AbbVie milestone, loss narrows", "summary": "CollPlant (Nasdaq: CLGN) reported a significant increase in 2025 GAAP revenue to $2.4 million, primarily driven by a $2 million milestone payment from AbbVie related to its dermal filler program. The company also managed to narrow its GAAP net loss to $11.5 million from $16.6 mil", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-5fe8ef42ec93.html", "source_name": "Stock Titan", "published_at": "2026-03-27T23:40:05", "published_display": "27 Mar 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE", "summary": "CollPlant Biotechnologies announced its 2025 financial results, reporting increased GAAP revenues of $2.4 million, mainly driven by a $2 million payment from AbbVie for a development milestone. The company highlighted advancements across its rhCollagen platform, including the lau", "url": "https://www.prnewswire.com/il/news-releases/collplant-biotechnologies-reports-2025-financial-results-and-provides-corporate-update-302726091.html", "source_name": "PR Newswire", "published_at": "2026-03-27T06:39:48", "published_display": "27 Mar 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRGdFS1Y2S2w4aUZhVEJGZzVZTlVrYlhRUW85VGItNzBrcU9kZUxoLW4tcHZNYkhJbUtVYWxrWkxLeDlrZlcydkFDd2lCNW1JQWZpZWNleDNOQ0paa05BY2QxN3RRUmJRdXVmaktiLXY2Sjkzb1hHc0otazJBeXI1cnV1bERKcDhqNEtnczhlbnB5MVJadlliMGlWMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Profit Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPd2xYSElOcVJzNkdrYVdERHpmX3NzNkMyODNuQ1dOV0VCUUlyX1k4NkVlN0lYbFhRR0ptd1ZLQndvMXBjVEZ3bWstUE9VRGZfNURSdE5zcUk1dUhJVTNpNFRLVjFSNC1IN1YzRDhsbUNraHctWnZvNUppcmNwdDZXYzR0SlM1TThSeGIxQTNjTDY?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Up 14%, But Some Insiders Miss Out", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can CollPlant Biotechnologies (NASDAQ:CLGN) Afford To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies (CLGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5EelRFVEUya3lwRWhLMEJoY0ZjR21HSFNmZDQ0NDJHYktNYXZCT2pkdXJKTDBVQmhkaVpBd0k0aU9lbko5Yjl4eUFPZHQtaEdQYWpZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:21:37+00:00", "published_display": "24 Apr 2025 23:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE", "summary": "CollPlant Biotechnologies Ltd. has filed a Form F-3 prospectus to register 31,047,068 ordinary shares for resale by selling shareholders. This registration covers 4,464,707 PIPE Shares and 26,582,361 ordinary shares issuable upon exercise of warrants issued in a private placement", "url": "https://www.stocktitan.net/sec-filings/CLGN/f-3-coll-plant-biotechnologies-ltd-foreign-issuer-shelf-registration-a281b3b9b9e4.html", "source_name": "Stock Titan", "published_at": "2026-07-10T02:10:25", "published_display": "10 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Files Prospectus for Resale of 31 Million Shares", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/collplant-biotechnologies-files-prospectus-resale-212952221.html", "source_name": "MT Newswires", "published_at": "2026-07-09T21:29:52+00:00", "published_display": "09 Jul 2026 21:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Calls July 29 Extraordinary Meeting to Approve Major Share Capital Increase", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxQTm1zQ2N2QkdmbWVCQTBVaDQxWC11M3FKckxLRWhlLXhtSUQ0S21SM2RIRTR4WUxqYk9XZmJhQXhtLUFrX242b1RMNU1aZDlKdUoza3ZFZjd5RUFVY2JpdklGblFwc0ZOSDFaVWdUamdYUWllek9qanBfUzhNaU9nNXFXR2l2VTJraWc4cGlIZTlHTENoY1ltNlVGM19lSnlOMFUtWm05bGEtOEhVLVh4ekZKem5LX2tyZkEybUdRd2ZBblRZWWV4aXdSbDl4N1psQmFRRU5nZzZrcjg3UkoxbEtXemhnaW9UdmQ1RzJzcW9mNTBma1h2TEZGd0FaVjl4cjhlSm01NzVvejZiNlMw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T20:34:00+00:00", "published_display": "08 Jul 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (NASDAQ: CLGN) targets 500M authorized shares in shareholder vote", "summary": "CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is seeking shareholder approval to significantly increase its authorized share capital from 30 million to 500 million Ordinary Shares. This move is intended to provide the company with greater flexibility to fulfill obligations from p", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-344729d5b9a1.html", "source_name": "Stock Titan", "published_at": "2026-07-08T13:10:31", "published_display": "08 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Q4 2025 Earnings: Wider\u2011Than\u2011Expected Loss Highlights Pre\u2011Revenue Challenges - Next Quarter Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPX0hCQ0hPLXJsYldaQl93QnFvWTQ3UmZmZG5TM08yX0ROSW8xTDMyM0xmTkp3aldxaTZ1ZUcwbDZaUWI0c1lvMUhaWklsT1Mzc3YtS0ZCRkRKSl9OOU1IM3RqNTJQV0pHaV9qVW9XS1BtMjFsenVOSXN4VU9aUHRRMHUxM2dGRm8zb1NVZE1fRXQ1bXBIb2Zick1zLUQ2eE95Yk82OTlDbnFDSWdiZ1BJY1ZKWVg3VmhEZHJSMVdKTGIyZDBmNkFQeERpVnRwc01vNW1CeTJSR2ttVUZib1RGYm85UWk5QQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Q4 2025 Earnings: Wider\u2011Than\u2011Expected Loss Highlights Pre\u2011Revenue Challenges", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQcGQzYmc3d18tQjBheS1vZk45dnZxX1BhQXlGYUY0Nlk1VUl2UjZ5bExnU1NMUXlvS0V1TDlBN3FCdGRfek1TZENXYzRSc09yMkUtTXNtWG94blNFM3pCVzEzYzhxd2dnVW9oYUp5VkJBd0dlSTVILVVEOURwRGZpSVpYVm9IcUllem5NN2JzS3lvS3RRZjAzRXJGY3VlZWxja2FVeElwWWc3MzFDcG5CWTNwTE56Y2d0ZTV5b3hkVjdDeW9XY0Q2ckJqQWxLaGVHbXg2MmdiQ1BfaWY3eWdxWjJRS0xQOTBx?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (Nasdaq: CLGN) raises $2.6M in share and warrant private deal", "summary": "CollPlant Biotechnologies has secured $2.6 million through a private placement of ordinary shares and warrants. The funding will be used for general corporate purposes, including working capital, R&D, and evaluating strategic business combinations. H.C. Wainwright & Co. served as", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-1bf3091dbf94.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:40:03", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/collplant-biotechnologies-announces-2-6-120000749.html", "source_name": "PR Newswire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant strikes $2.6M private placement, with warrants attached", "summary": "CollPlant Biotechnologies has announced a definitive agreement for a $2.6 million private placement. The company will issue 7,647,061 ordinary shares (or equivalents) along with Series A and B warrants, priced at $0.34 per share and accompanying warrants. The proceeds are intende", "url": "https://www.stocktitan.net/news/CLGN/collplant-biotechnologies-announces-2-6-million-private-ja22sm9ol512.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:24", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Ltd. announced that it expects to receive $2.6 million in funding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQWkUwckZOa1RjMDRXMEt2NDBnLUNGbWMyUU9nUnZxSmh0Mnl0VEZCLUpWNTlMWFRBVW9EN1A0eVF3ZWJvdzZXSFl3aFhEb3F4MENOd2QwU1h1VXZEQXFTYUpfRXRiNW4wdFNFZHpXTXl4VGFqSG5xa1NCWDlmOER6Zk43NDAtUEhxdFJMZk5QenhVTEFqMzdJeHE0TmU1UUttcE9KT3FfWWVHZFlRZ3lWX2dMNHFBOUdxZHdWOXlnQWtNWEE1cW5uMjN2X3piN3BOQzNVM1VHOGgzVHRqZXVDbg?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T22:00:00+00:00", "published_display": "29 Jun 2026 22:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Ltd Actuals & Estimates (NASDAQ:CLGN)", "summary": "This article provides an overview of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) financial actuals and estimates, including its current stock price, historical performance, market capitalization, and upcoming earnings report. It highlights key financial figures such as recent ea", "url": "https://www.tradingview.com/symbols/NASDAQ-CLGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:42", "published_display": "25 Jun 2026 14:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Faces Pressure Near Key Support - Fair Value Gap", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPQUFzVjdQejN5azV5Wm50aWUwNUFpUWpCZ19xYWk2T01KbHRRZFhUZS04VV9nSkxfZHZXdURmVHZNcDl3YWx0UXZZclRXaW1HNlR1Wk54a2ZDRzBicXo3X25yNXc4Z1JEdjIyWkt4VHN1cVJEVEpWbU9qM19sRko2a3hoT2tDdTdWVE1xbEV1TjVxdkFJVHFtNnRxbFFKRkh3UHliaXRqcTRudzVnb3c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Collplant Biotechnologies Ltd (CLGN), noting that no earnings forecast score is currently available from TradingKey. It highlights an average analyst price target of USD 11.50 for CLGN, with revenue expected to be USD 9.80M for the n", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-21T21:10:17", "published_display": "21 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Institutional Confidence", "summary": "This article analyzes Collplant Biotechnologies Ltd (CLGN)'s institutional confidence score, which is currently 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 27.21% quarter-over-quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clgn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T17:39:23", "published_display": "18 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5WLXdUdVFqbGYwUHplanloWmh4TFY2YUppaElyT01pdGE1b0VSOGdYUF93SHpaSWVJM1FKZllMaFNTUWhBRWZlY1FLNFltMmNDQ09tMjl5b1RMOFFnSk50b2p2RmpZZGU4dVQ2LUoxNENXVl9YSFcw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:53:40+00:00", "published_display": "18 Jun 2026 10:53", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies Ltd (CLGN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Collplant Biotechnologies Ltd (CLGN) currently holds a financial score of 6.04, placing it 296th out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company recently reported a significant year-over-yea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clgn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:38", "published_display": "18 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CollPlant eyes deals after 50% staff cut and Q1 loss", "summary": "CollPlant Biotechnologies reported a widened GAAP net loss of $3.1 million in Q1 2026, with revenue significantly down to $73,000 from $2.1 million in Q1 2025 due to a non-recurring milestone payment last year. The company reduced its workforce by approximately 50% and initiated ", "url": "https://www.stocktitan.net/news/CLGN/collplant-biotechnologies-reports-2026-first-quarter-financial-q747wn7a7tlf.html", "source_name": "Stock Titan", "published_at": "2026-06-15T15:10:42", "published_display": "15 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents", "summary": "CollPlant (CLGN) is facing a Nasdaq deadline of September 21 to regain compliance with the $1 minimum bid price rule. The company's stock is currently trading under 40 cents, and its Q1 revenue was significantly down due to the absence of a milestone payment received the previous", "url": "https://www.bez-kabli.pl/collplant-heads-toward-nasdaq-deadline-with-stock-at-40-cents/", "source_name": "Bez Kabli", "published_at": "2026-06-04T04:11:01", "published_display": "04 Jun 2026 04:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLGN - CollPlant Biotechnologies Ltd Stock Price and Quote", "summary": "This article provides comprehensive stock information for CollPlant Biotechnologies Ltd (CLGN), including real-time quotes, financial data, company overview, recent news, and analyst ratings. It highlights that the company's last close was at $0.3402, with key financial metrics l", "url": "https://finviz.com/stock?t=CLGN", "source_name": "Finviz", "published_at": "2026-06-03T11:11:50", "published_display": "03 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline", "summary": "CollPlant Biotechnologies reported a wider net loss of $3.1 million in Q1 2026, with revenue dropping significantly to $73,000 from $2.1 million a year prior. The company is actively exploring strategic alternatives, including collaborations for its next-generation dermal fillers", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CLGN-Q/pressreleases/2215852/collplant-biotechnologies-posts-wider-q1-loss-as-it-explores-strategic-alternatives-and-advances-regenerative-aesthetics-pipeline/", "source_name": "The Globe and Mail", "published_at": "2026-05-30T22:09:24", "published_display": "30 May 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (CLGN) Hovers Near Support at $0.38 After Marginal Decline - SuperTrend Flip", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNQlNERTBVTVVBLWtWYUVuWGZ2OUgzMlFZODVvWFRXVVFTdUkwdmplTnE5MVdWaU1scHp0YWFBUWN2VHhCTWhLRVA2TlhFTHdFODRSWGJ1RjVqZk1qb2JwSk94WFpybExTUVNsa1N2LU9GNC1GVGMtZ0JyLWdMemV1Ylh2VnU1azFaMURSZUdSMndwdlZYQ0gwNXpXUFdhRi1qbHQycWVncUNVYW1KaTJGYklpSWgta1lyMzl4U2gxNFBjTmxoYzVUOA?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (NASDAQ: CLGN) Q1 2026 revenue plunges as losses deepen", "summary": "CollPlant (NASDAQ: CLGN) reported a significant decline in Q1 2026 revenue to $73,000 from $2.055 million the previous year, primarily due to the non-recurrence of a $2.0 million milestone payment. The company's GAAP net loss widened to $3.1 million, or $0.23 per share, compared ", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-d216415ba7c4.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:39:39", "published_display": "29 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/collplant-biotechnologies-reports-2026-first-110000012.html", "source_name": "PR Newswire", "published_at": "2026-05-29T11:00:00+00:00", "published_display": "29 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLGN Forecast \u2014 Price Prediction for 2026. Should I Buy CLGN?", "summary": "This article provides a price prediction for Collplant Biotechnologies Ltd (CLGN) stock for 2026 and beyond, based on an advanced algorithm. While short-term predictions show potential volatility and a \"Strong Sell\" recommendation due to negative signals and a falling trend, long", "url": "https://intellectia.ai/stock/CLGN/forecast", "source_name": "Intellectia AI", "published_at": "2026-05-26T02:39:28", "published_display": "26 May 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE", "summary": "CollPlant Biotechnologies has released its second-quarter financial results for 2024, accompanied by a corporate update. This announcement was made via a press release distributed by Quantisnow, a platform providing real-time market data and news to retail investors. The update w", "url": "https://www.quantisnow.com/insight/collplant-biotechnologies-reports-2024-second-quarter-financial-results-and-provides-corporate-update-5665647", "source_name": "Quantisnow", "published_at": "2026-05-23T08:09:27", "published_display": "23 May 2026 08:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (Nasdaq:CLGN) - Stock Analysis", "summary": "This Simply Wall St analysis provides a comprehensive overview of CollPlant Biotechnologies (CLGN), a regenerative and aesthetic medicine company. It highlights a US$6.0m market cap, analyst target price of US$11.56, and significant risks including high share price volatility, de", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clgn/collplant-biotechnologies", "source_name": "Simply Wall Street", "published_at": "2026-05-06T11:09:19", "published_display": "06 May 2026 11:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] CollPlant Biotechnologies Ltd SEC Filing", "summary": "This article reports on an SEC Filing (Form EFFECT) by CollPlant Biotechnologies Ltd (NASDAQ: CLGN). The filing indicates a \"Notice of Effectiveness\" with an effectiveness date of April 21, 2026, at 4:30 P.M. The article details the company's CIK, file number, and provides links ", "url": "https://www.stocktitan.net/sec-filings/CLGN/effect-coll-plant-biotechnologies-ltd-sec-filing-952782470398.html", "source_name": "Stock Titan", "published_at": "2026-04-25T23:39:54", "published_display": "25 Apr 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Half the staff cut as CollPlant resets after AbbVie ends deal", "summary": "CollPlant (CLGN) has announced the termination of its development agreement with AbbVie, leading to a significant company-wide cost-reduction plan that includes a 50% workforce reduction. These measures are expected to extend the company's cash runway into Q4 2026. CollPlant is n", "url": "https://www.stocktitan.net/news/CLGN/coll-plant-issues-letter-to-38jzljmyv08n.html", "source_name": "Stock Titan", "published_at": "2026-04-23T17:10:12", "published_display": "23 Apr 2026 17:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (CLGN) registers 3.296M shares for resale; warrants convertible into shares", "summary": "CollPlant Biotechnologies Ltd. (CLGN) has registered 3.296 million ordinary shares for resale, stemming from the exercise of private placement and placement agent warrants issued in February 2026. The company will not receive proceeds from this resale, but could gain approximatel", "url": "https://www.stocktitan.net/sec-filings/CLGN/424b3-coll-plant-biotechnologies-ltd-prospectus-filed-pursuant-to-rul-3aeca471f162.html", "source_name": "Stock Titan", "published_at": "2026-04-22T05:09:51", "published_display": "22 Apr 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead", "summary": "CollPlant has announced the termination of its development agreement with AbbVie, aiming to seek new strategic partners in the medical aesthetics market for 2026. The company is implementing a cost-reduction plan, including a 50% workforce cut, to extend its cash runway into Q4 2", "url": "https://intellectia.ai/news/stock/collplant-ends-abbvie-partnership-eyes-new-opportunities-ahead", "source_name": "Intellectia AI", "published_at": "2026-04-13T14:09:59", "published_display": "13 Apr 2026 14:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50%", "summary": "CollPlant (NASDAQ: CLGN) announced that AbbVie's Allergan Industrie SAS has terminated their 2021 development agreement for a dermal and soft tissue filler, effective June 8, 2026. In response, CollPlant is implementing a cost-reduction plan, including a 50% workforce cut, to ext", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-a12d95d28f6c.html", "source_name": "Stock Titan", "published_at": "2026-04-13T11:40:15", "published_display": "13 Apr 2026 11:40", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement", "summary": "CollPlant Biotechnologies received a notification from Nasdaq regarding its minimum bid requirement. This alert was sent to Quantisnow Plus members shortly after publication. The company's stock symbol is CLGN and it is categorized under Health Care.", "url": "https://www.quantisnow.com/insight/collplant-biotechnologies-receives-nasdaq-notification-regarding-minimum-bid-requirement-6466833", "source_name": "Quantisnow", "published_at": "2026-04-12T12:39:40", "published_display": "12 Apr 2026 12:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLGN SEC Filings - Collplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms", "summary": "This page on Stock Titan provides comprehensive access to SEC filings for Collplant Biotechnologies Ltd (CLGN), including annual reports (20-F), quarterly reports via 6-K submissions, and documentation of material events. It details the company's regulatory disclosures as a forei", "url": "https://www.stocktitan.net/sec-filings/CLGN/page-4.html", "source_name": "Stock Titan", "published_at": "2026-03-31T20:40:03", "published_display": "31 Mar 2026 20:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies (NASDAQ: CLGN) registers 3.296M shares for resale", "summary": "CollPlant Biotechnologies (NASDAQ: CLGN) has registered 3.296 million ordinary shares for resale by existing selling shareholders. These shares are issuable upon the exercise of Private Placement Warrants from a February 2026 financing round. The company will not receive proceeds", "url": "https://www.stocktitan.net/sec-filings/CLGN/f-1-coll-plant-biotechnologies-ltd-foreign-issuer-ipo-registration-7b6caf45d282.html", "source_name": "Stock Titan", "published_at": "2026-03-31T08:40:44", "published_display": "31 Mar 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Launches Redesigned Corporate Website", "summary": "CollPlant Biotechnologies has launched a newly redesigned corporate website. This information was released via Quantisnow, a real-time market data and news platform specializing in aggregating financial information for retail investors. The article briefly mentions recent analyst", "url": "https://www.quantisnow.com/insight/collplant-biotechnologies-launches-redesigned-corporate-website-6455705", "source_name": "Quantisnow", "published_at": "2026-03-29T07:10:13", "published_display": "29 Mar 2026 07:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant (Nasdaq: CLGN) 2025 revenue jumps on AbbVie milestone, loss narrows", "summary": "CollPlant (Nasdaq: CLGN) reported a significant increase in 2025 GAAP revenue to $2.4 million, primarily driven by a $2 million milestone payment from AbbVie related to its dermal filler program. The company also managed to narrow its GAAP net loss to $11.5 million from $16.6 mil", "url": "https://www.stocktitan.net/sec-filings/CLGN/6-k-coll-plant-biotechnologies-ltd-current-report-foreign-issuer-5fe8ef42ec93.html", "source_name": "Stock Titan", "published_at": "2026-03-27T23:40:05", "published_display": "27 Mar 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE", "summary": "CollPlant Biotechnologies announced its 2025 financial results, reporting increased GAAP revenues of $2.4 million, mainly driven by a $2 million payment from AbbVie for a development milestone. The company highlighted advancements across its rhCollagen platform, including the lau", "url": "https://www.prnewswire.com/il/news-releases/collplant-biotechnologies-reports-2025-financial-results-and-provides-corporate-update-302726091.html", "source_name": "PR Newswire", "published_at": "2026-03-27T06:39:48", "published_display": "27 Mar 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRGdFS1Y2S2w4aUZhVEJGZzVZTlVrYlhRUW85VGItNzBrcU9kZUxoLW4tcHZNYkhJbUtVYWxrWkxLeDlrZlcydkFDd2lCNW1JQWZpZWNleDNOQ0paa05BY2QxN3RRUmJRdXVmaktiLXY2Sjkzb1hHc0otazJBeXI1cnV1bERKcDhqNEtnczhlbnB5MVJadlliMGlWMA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Profit Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPd2xYSElOcVJzNkdrYVdERHpmX3NzNkMyODNuQ1dOV0VCUUlyX1k4NkVlN0lYbFhRR0ptd1ZLQndvMXBjVEZ3bWstUE9VRGZfNURSdE5zcUk1dUhJVTNpNFRLVjFSNC1IN1YzRDhsbUNraHctWnZvNUppcmNwdDZXYzR0SlM1TThSeGIxQTNjTDY?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CollPlant Biotechnologies Up 14%, But Some Insiders Miss Out", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can CollPlant Biotechnologies (NASDAQ:CLGN) Afford To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collplant Biotechnologies (CLGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5EelRFVEUya3lwRWhLMEJoY0ZjR21HSFNmZDQ0NDJHYktNYXZCT2pkdXJKTDBVQmhkaVpBd0k0aU9lbko5Yjl4eUFPZHQtaEdQYWpZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:21:37+00:00", "published_display": "24 Apr 2025 23:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 51, "sentiment_summary": {"positive": 10, "negative": 17, "neutral": 24, "score": 46, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.55, "count": 23}, {"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 10, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 0.37, "latest_week": "2026-07-10", "one_week_move": 8.2, "four_week_move": 8.5, "twelve_week_move": 3.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.151628, "market_dynamics_buy_signal": false, "relative_strength": -78.58345, "fair_value_gap": -89.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.7114, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.2% over one week, +8.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Donan\u0131mHaber", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "PR Newswire", "count": 3}, {"label": "Quantisnow", "count": 3}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 23}, {"label": "Market update", "count": 18}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.2% over one week, +8.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE"}], "updated_at": "2026-07-16T05:41:26.522063+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}